PRODUCTS SOLD ON PEPTIDESLABUSA.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABUSA.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
Price range: $187.50 through $334.50
Mazdutide Peptide USA – Buy Online | In Stock & Ready to Ship
Buy Mazdutide in the USA with fast domestic shipping and guaranteed ≥99% purity — fully verified with COA and HPLC documentation. A trusted choice for USA research teams studying GLP-1 and glucagon receptor dual agonism, metabolic regulation and weight management pathways, Mazdutide is available in multiple formats to suit varying project needs. No international delays — just reliable, domestically sourced peptides USA researchers can count on.
For research use only. Not intended for human or veterinary use.
Mazdutide is a once-weekly GLP-1 receptor and glucagon receptor (GCGR) dual agonist — the world’s first approved GCG/GLP-1 dual receptor agonist — studied for its complementary effects on appetite suppression, energy expenditure, glucose regulation, and hepatic fat metabolism, making it one of the most actively researched metabolic peptides available in the USA today.
Researchers, labs, and institutions across the United States can source verified, research-grade Mazdutide with fast dispatch, full documentation, and third-party verified purity.
✅ ≥99% Purity — HPLC & Mass Spectrometry Verified ✅ Batch-Specific Certificate of Analysis (CoA) Included ✅ Third-Party Tested | GMP Manufactured ✅ Fast Dispatch to USA — Tracked Shipping Available
Mazdutide — also known by its developmental designations IBI362 and LY3305677 — is a synthetic once-weekly mammalian oxyntomodulin (OXM) analogue engineered to act as a potent dual agonist at both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). It was developed by Innovent Biologics under an exclusive licensing agreement with Eli Lilly and Company, and has since become one of the most comprehensively studied metabolic peptides in the global research pipeline.
Mazdutide’s design is rooted in the biology of oxyntomodulin — a naturally occurring proglucagon-derived peptide that stimulates both GLP-1 and glucagon receptors simultaneously. By engineering a long-acting analogue of this natural dual agonist, researchers gained access to a tool compound that targets two metabolic receptor systems with distinct but synergistic mechanisms: the GLP-1 pathway for appetite suppression, insulin secretion, and gastric emptying regulation, and the GCGR pathway for increased energy expenditure, enhanced fatty acid oxidation, and improved hepatic fat metabolism.
Mazdutide is the world’s first approved GCG/GLP-1 dual receptor agonist for both glycemic control and weight management, having received approvals from China’s NMPA in 2025. It is not approved by the FDA for therapeutic use in the United States and is supplied here exclusively for licensed laboratory research purposes.
In research settings, Mazdutide has been studied for its dual-pathway effects across metabolic, hepatic, cardiovascular, cognitive, and renal biology contexts. Studies have explored its influence on:
Mazdutide is a research compound only and is not approved for human therapeutic use in the United States.
Mazdutide has one of the most current and rapidly expanding research profiles of any metabolic peptide in this catalog, with Phase 3 clinical data published in the New England Journal of Medicine and Nature in 2025, alongside preclinical mechanistic studies presented at the American Diabetes Association’s Scientific Sessions.
GLORY-1 — Phase 3 Weight Management Trial (NEJM, 2025) The GLORY-1 trial was a multi-center, randomized, double-blind, placebo-controlled Phase 3 study evaluating Mazdutide in Chinese adults with overweight or obesity. At week 48, the treatment difference for the mean percentage weight change between mazdutide 6 mg and placebo was -14.31% for the treatment-policy estimand. Mazdutide treatment was also associated with meaningful improvements across multiple cardiometabolic markers including waist circumference, lipid levels, blood pressure, uric acid, and liver fat content — positioning it as a broad-spectrum metabolic research tool beyond weight reduction alone. The GLORY-1 data were incorporated into China’s clinical consensus guidelines for obesity management following publication.
DREAMS-1 and DREAMS-2 — Phase 3 Glycemic Control Trials (Nature, 2025) The results of two Phase 3 clinical studies of mazdutide in Chinese adults with type 2 diabetes (DREAMS-1, DREAMS-2) were published back-to-back in Nature as Accelerated Article Previews. These trials examined Mazdutide as both monotherapy (DREAMS-1) and as add-on therapy to oral antidiabetic drugs (DREAMS-2), with findings demonstrating robust HbA1c reduction and weight loss benefits across both study designs — reinforcing the value of dual receptor engagement for simultaneous glycemic and metabolic control in research models.
Hepatic Fat Metabolism Research (ADA 2025) Research presented at the American Diabetes Association’s 2025 Scientific Sessions examined mazdutide’s hepatic effects compared to semaglutide. Liver RNA-sequencing and KEGG enrichment analysis showed that mazdutide predominantly activated oxidative phosphorylation and fatty acid degradation pathways, and lipid metabolism-related genes including Ehhadh, Cyp4a14, and Fgf21 were upregulated, indicating facilitated fatty acid oxidation in the liver compared to semaglutide. This GCGR-driven hepatic fatty acid oxidation mechanism represents a research advantage that GLP-1 monotherapy compounds cannot replicate.
Uric Acid and Hyperuricemia Research (ADA 2025) SnRNA-Seq analysis shows that mazdutide increases GCGR expression in hepatocytes, while semaglutide slightly inhibits it. Studies in hyperuricemic rats demonstrated that Mazdutide significantly lowered serum uric acid by enhancing fatty acid oxidation and reducing purine precursor production in hepatocytes — a metabolic benefit not observed with GLP-1R monotherapy, attributable specifically to the GCGR activation component.
Diabetes-Associated Cognitive Dysfunction Research (eBioMedicine / Lancet, 2025) A 2025 study published in eBioMedicine examined Mazdutide in the db/db diabetic mouse model against dulaglutide (a GLP-1R monotherapy). Compared to dulaglutide, mazdutide significantly improved cognitive performance in db/db mice, with pathological assessments revealing improvements in neuronal structure and brain tissue integrity. Multi-omics analyses further identified distinct molecular pathways involved in neuroprotection, energy metabolism, and synaptic plasticity, suggesting that dual GLP-1/GCGR activation contributes to enhanced cognitive resilience. Researchers identified GCGR activation’s ability to counteract glutamate excitotoxicity as a pathway uniquely targeted by dual agonists — not accessible through GLP-1R signaling alone.
Meta-Analysis of Randomized Controlled Trials A published systematic review and meta-analysis of Mazdutide RCTs confirmed that Mazdutide was more effective than placebo in reducing weight, systolic and diastolic blood pressure, total cholesterol, triglycerides, LDL and HDL among patients with and without diabetes, with weight reduction more significant in non-diabetic participants compared to diabetics. The meta-analysis identified gastrointestinal side effects (nausea, vomiting, decreased appetite) and modest heart rate increases as the primary adverse events — consistent with the broader GLP-1/glucagon agonist class profile.
High-Dose Phase 1b Research (eClinicalMedicine / Lancet) Phase 1b dose-escalation research examining Mazdutide up to 9 and 10 mg doses found the compound well tolerated with a favorable safety profile at higher dose ranges, with 12-week body weight loss achieving up to 6.4% at 6 mg — supporting continued investigation of higher-dose regimens in larger Phase 2 and 3 programs.
All clinical data referenced is from trials conducted in approved research contexts outside the USA. Mazdutide is not FDA-approved and is supplied here for licensed laboratory research purposes only.
When you buy Mazdutide in the USA through our platform, every order includes:
We supply USA research peptides to licensed researchers, universities, and institutions — with cold-chain compliant packaging designed to maintain peptide integrity throughout transit.
| Parameter | Specification |
|---|---|
| Purity | ≥99% (HPLC & MS Verified) |
| Also Known As | IBI362, LY3305677, OXM3 |
| Classification | GLP-1R / GCGR Dual Agonist |
| Origin | Mammalian oxyntomodulin (OXM) analogue |
| Administration Frequency | Once-weekly (in clinical research contexts) |
| Form | Lyophilized Powder |
| Solubility | Sterile water / PBS |
| Storage (powder) | -20°C, stable 24+ months |
| Storage (reconstituted) | 2–8°C, use within 2–4 weeks |
| Available Sizes | 2mg |
Allow the vial to reach room temperature before opening. Add sterile water or PBS slowly down the inside wall of the vial and swirl gently — do not shake. Prepare working concentrations by diluting as required for your assay system. Aliquot and store at -80°C for longer-term stability. Avoid repeated freeze-thaw cycles.
| Feature | Mazdutide | Semaglutide | CagriSema | Tirzepatide |
|---|---|---|---|---|
| Mechanism | GLP-1R + GCGR | GLP-1R only | GLP-1R + Amylin/Calcitonin | GLP-1R + GIPR |
| Receptors Targeted | 2 (GLP-1R, GCGR) | 1 | 2 (distinct) | 2 (overlapping) |
| Energy Expenditure via GCGR | Yes | No | No | No |
| Hepatic Fat Oxidation | Superior vs GLP-1 alone | Standard | Moderate | Moderate |
| Phase 3 Weight Loss Data | ~14.3% at 48 weeks (6mg) | ~14.9% at 68 weeks | ~20.4% at 68 weeks | ~20–22% at 72 weeks |
| Cognitive Research | Yes (2025 db/db data) | Limited | No | Limited |
| Uric Acid Research | Yes (GCGR pathway) | No | No | Limited |
| FDA Approved | No | Yes | No (filed Dec 2025) | Yes |
| Approved (Other) | China (NMPA, 2025) | Multiple countries | Pending | Multiple countries |
Can I buy Mazdutide in the USA? Yes. We supply research-grade Mazdutide (IBI362) with fast tracked dispatch across the United States for licensed laboratory research use. All orders include full purity documentation and integrity-maintained packaging.
What is the difference between Mazdutide and Semaglutide? Semaglutide is a GLP-1R monoagonist — it targets one receptor. Mazdutide is a dual agonist that targets both GLP-1R and the glucagon receptor (GCGR). The GCGR component adds a distinct mechanism not present in semaglutide: increased energy expenditure, enhanced fatty acid oxidation in the liver, and GCGR-specific pathways studied in hyperuricemia and cognitive function research. Research has shown Mazdutide produces superior hepatic fat reduction compared to semaglutide — a difference directly attributable to GCGR activation.
What is Mazdutide’s alternative name IBI362? IBI362 is Mazdutide’s Innovent Biologics internal developmental designation. LY3305677 is the Eli Lilly designation from the licensing partnership. OXM3 is an early research designation. All four names — Mazdutide, IBI362, LY3305677, and OXM3 — refer to the same compound.
Is Mazdutide approved in the USA? No. Mazdutide is not FDA-approved for any therapeutic use in the United States. It received approvals from China’s NMPA in June 2025 (weight management) and September 2025 (glycemic control). It is supplied here exclusively for licensed laboratory research use in the USA.
How does the GCGR component of Mazdutide differ from the GLP-1R component? The GLP-1R component primarily reduces appetite and delays gastric emptying — decreasing caloric intake. The GCGR component increases resting energy expenditure through thermogenesis and fatty acid oxidation — increasing caloric burn. These are complementary mechanisms: GLP-1R reduces energy in, GCGR increases energy out. Crucially, Mazdutide’s design balances these two receptor activities so that the hyperglycemia that would normally result from isolated glucagon receptor stimulation is counteracted by the concurrent GLP-1R-mediated insulin secretion.
What purity level should research-grade Mazdutide be? ≥98% is the accepted minimum for research-grade peptides, though ≥99% is preferred for receptor binding, metabolic pathway, and in vitro assay work. All of our USA research peptides — including Mazdutide — are HPLC and mass spectrometry verified to ≥99%.
How quickly is Mazdutide delivered in the USA? Orders are dispatched promptly with tracked shipping. Most USA orders arrive within 3–5 business days.
Where can I find Mazdutide for sale in the USA? We offer research-grade Mazdutide (IBI362) for sale in the USA exclusively for licensed laboratory research use, with full documentation and verified purity included as standard with every order.
Research Disclaimer: Mazdutide (IBI362) is supplied exclusively for legitimate scientific research purposes in licensed laboratory environments. This product is not FDA-approved and is not intended for human consumption, self-administration, or therapeutic use of any kind in the United States. It must be handled by qualified researchers in accordance with all applicable US federal and state regulations and institutional ethics guidelines. By purchasing, you confirm that this compound will be used solely for approved in-vitro or pre-clinical research.
Receive News
